[Skip to Content]
Access to paid content on this site is currently suspended due to excessive activity being detected from your IP address 54.147.238.168. Please contact the publisher to request reinstatement.
[Skip to Content Landing]
Views 1,039
Citations 0
Comment & Response
December 15, 2015

Pioglitazone Use and Risk of Bladder Cancer

Author Affiliations
  • 1Department of Medicine, Johns Hopkins University, Baltimore, Maryland
  • 2Department of Biomathematics, University of California, Los Angeles
JAMA. 2015;314(23):2567-2568. doi:10.1001/jama.2015.13912

To the Editor Dr Lewis and colleagues1 reported that more than 4 years’ duration of pioglitazone use was not associated with a statistically significant increased risk of bladder cancer (hazard ratio, 1.22; 95% CI, 0.92-1.61) after adjusting for several covariates, including calendar year at cohort entry.

This result contrasts with their previous analysis,2 and an accumulating body of evidence from other trials and observational studies, which all support an increased risk of bladder cancer with pioglitazone.3 As a result, the International Agency for Research on Cancer classified pioglitazone as a probable human carcinogen (grade 2A).4

First Page Preview View Large
First page PDF preview
First page PDF preview
×